MAR 1 3 2002 2

REQUEST FOR

CONTINUED EXAMINATION (RCE) **TRANSMITTAL**

Subsection (b) of 35 USC 132, effective on May 29, 2000, provides for continued examination of an utility or plant application

filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA)

			623
Application No.	09/142,557	E	$\frac{1}{2}$
Filing Date	September 11, 1998	子 3	m
First Named Inventor	Linda M. PILARSKI	R	\Box
Group Art Unit	1623	2 1 ER	
Examiner Name	K. Fonda	160	
Attorney Docket No	205220	0/2900	
		8	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. IS A REQUEST FOR CONTINUED EXAMINATION (RCE) UNDER 37 OFR 1.114 OF THE ADOVE-IDENTIFIED Application.

NOTE: 37 CFR 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 CFR 1.53(d) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000). 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE

1.	Sul	bmi	ssion required under 37 CFR 1.114						
	a.		Previously submitted						
		i.	☐ Consider the amendment(s)/reply under						
			(Any unentered amendment(s) referred to above w						
		ii.	Consider the arguments in the Appeal Brief or Reply Brief previously filed on						
		iii.	Other:	,					
	b.	\boxtimes	Enclosed	03/19/2002 SSANDARA 00000003 09142557					
		i.	Response to Office Action	01 FC:179 740.00 07					
		ii.	☐ Affidavit(s)/Declaration(s)	\					
		iii.							
		iv.	Form PTO-1449	03/19/2002 SSAHDARA 00000003 09142557					
		٧.		0-7449 920.00 GP					
		vi.	Other: Return Receipt Postcard	92 PC1117					
2.	Mis		laneous						
	a.		Suspension of action on the above-identified	application is requested under 37 CFR 1.103 for	a period of				
		_		eed 3 months; fee under 37 CFR 1.17(i) required.)					
	b.		Applicant claims small entity status. See 37	CFR 1.27					
	C.		Other:						
3.	Fee	es 1	The RCE fee under 37 CFR 1.17(e) is required by 37 CFI	R 1.114 when the RCE is filed.					
	a.	\boxtimes	The following fees are enclosed:						
		i.	RCE fee of \$740.00 (large entity) require	ed under 37 CFR 1.17(e)					
		ii.		20.00 (37 CFR 1.136 and 1.17)					
		iii.	☐ Suspension of action fee of \$130.00 (37	CFR 1.17(i))					
		iv.	Other:						
			_	TOTAL FEES ENCLOSED	\$1,660.00				
	b.	\boxtimes	Check in the amount of \$1,660.00 enclosed						
		▤	The Commissioner is hereby authorized to c	harge the above fees to Deposit Account No.					
		_	12-1216						
	d.	\boxtimes	The Commissioner is hereby authorized to discredit any overpayments to Deposit Account	harge any deficiencies in the above fees or to No. 12-1216					



RECEIVED

MAR 2 1 2002

TECH CENTER 1600/2900

Application	No.	09/142,557
-------------	-----	------------

Attorney Docket No. 205220

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT REQUIRED						
Name (Print/Type)	Salim A. Hasan	11		Registration	on No. (Attorney/Agent)	38,175
Signature	(A) (C			Date	March 13, 2002	

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8					
I hereby certify that this RCE Transmittal is, on the date indicated below, being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box RCE, Washington, DC 20231, or being facsimile transmitted to the U.S. Patent and Trademark Office.					
Name (Print/Type)					
Signature	Date	March 13, 2002			

CERTIFICATE OF MAILING UNDER 37 CFR 1.10						
I hereby certify that this RCE Transmittal and all accompanying documents are being deposited with the United States Postal Service on March 13, 2002, in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR 1.10, Mailing Label Number EL643546333US, addressed to: Box RCE, Commissioner for Patents, Washington, D.C. 20231.						
Name (Print/Type)	Irina L. Mikitiouk			·		
Signature	2, Milit	rouh	Date	March 13, 2002		



RESPONSE UNDER 37 CFR 1.116 EXPEDITED PROCEDURE EXAMINING GROUP 1623

PATENT

Attorney Docket No. 205220

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Pilarski

For:

Group Art Unit: 1623

Application No. 09/142,557

Examiner: K. Fonda

Filed: September 11, 1998

METHODS FOR CELL MOBILIZATION

USING IN VIVO TREATMENT

WITH HYALURONAN

RESPONSE TO OFFICE ACTION

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated September 13, 2001, please consider the following amendments and remarks. This response is timely since it is accompanied by (a) a Request for Continued Examination (R.C.E.) pursuant to 37 C.F.R. § 1.114, and (b) a petition and a fee for a three-month extension of time for filing a response pursuant to 37 C.F.R. § 1.136(a).

AMENDMENTS

IN THE CLAIMS:

Please cancel claims 103, 106-111, 114-126, 130-136, 138, 139, 141, 143, and 144 without prejudice.

Please add the following new claims:

171. (New) A method for releasing cells from bone marrow and other tissue sites of a patient into blood of the patient comprising administering to the patient an